ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
Open access · hybridAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Association of miR-199a-3p and CDK7 expression with clinicopathological features of breast cancer.Molecular biology reports · 2026Article
- DNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases.Cell reports. Medicine · 2026Article
- Distinction between primary and metastatic mucinous ovarian carcinoma from histopathology images using deep learning.NPJ digital medicine · 2026Article
- Histopathology images-based deep learning prediction of prognosis in primary mucinous ovarian carcinoma.Frontiers in oncology · 2026Article
- A 5-marker immunohistochemical panel of CK17, MEP1A, PAX8, SMAD4, and CDX2 to distinguish ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma.Histopathology · 2026Article
- NRF2 promotes the migration of ovarian cancer cell lines by targeting TAGLN mediated epithelial-mesenchymal transition.Journal of ovarian research · 2025Article
- Cellular origins of mucinous ovarian carcinoma.The Journal of pathology · 2025Review
- Integrated multi-omics analysis reveals the immunotherapeutic significance of tumor cells with high FN1 expression in ovarian cancer.Frontiers in molecular biosciences · 2025Article
- A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.NAR genomics and bioinformatics · 2024Article
- Therapeutic developments in pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2024Review
- Review
- Profiling the immune landscape in mucinous ovarian carcinoma.Gynecologic oncology · 2023Article
- Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression.Cells · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
114 authors at 20 institutions in 10 countries.
Nicola S MeagherSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-9134-2118
Kylie L GorringePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-5681-2022
Matthew WakefieldThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0001-6624-4698
Adelyn BolithonSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-1914-6125
Chi Nam Ignatius PangSchool of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0001-9703-5741
Derek S ChiuBritish Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.ORCID 0000-0002-7591-4881
Michael S AnglesioBritish Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.ORCID 0000-0003-1639-5003
Kylie-Ann MallittSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-5722-7287
Jennifer A DohertyHuntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1454-8187
Holly R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-2572-6727
Joellen M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.ORCID 0000-0002-0990-9339
Andrew BerchuckDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-1940-1467
Kara L Cushing-HaugenProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-2993-0191
Ksenia ChezarDepartment of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.ORCID 0000-0003-0370-9448
Angela ChouThe Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0001-9212-6927
Adeline TanDivision of Obstetrics and Gynaecology, Medical School, University of Western Australia, Crawley, Western Australia, Australia.ORCID 0000-0001-9270-7799
Jennifer AlsopCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-0728-0557
Ellen BarlowGynaecological Cancer Centre, Royal Hospital for Women, Sydney, New South Wales, Australia.ORCID 0000-0001-7864-1252
Matthias W BeckmannDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-8441-693X
Jessica BorosThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-4090-4253
David D L BowtellPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-9089-7525
AOCS Group
Alison H BrandThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-7975-6326
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-5738-6683
Ian CampbellPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-7773-4155
Dane CheasleyPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-1170-4690
Joshua CohenDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.ORCID 0000-0002-9454-3254
Cezary CybulskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.ORCID 0000-0002-2819-3057
Esther ElishaevDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-6271-0222
Ramona ErberInstitute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0003-0315-1229
Rhonda FarrellThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-7036-8968
Anna FischerInstitute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0001-5120-2065
Zhuxuan FuDepartment of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.ORCID 0000-0002-9190-195X
Blake GilksDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-7889-8250
Anthony J GillThe Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0002-9447-1967
Australian Pancreatic Genome Initiative
Charlie GourleyNicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-2377-7221
Marcel GrubeDepartment of Women's Health, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0002-6609-8827
Paul R HarnettThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-7021-0642
Arndt HartmannInstitute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0002-4860-4626
Anusha HettiaratchiThe Health Precincts Biobank (formerly the Health Science Alliance Biobank), UNSW Biospecimen Services, Mark Wainwright Analytical Centre, University of New South Wales Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-5928-2300
Claus K HøgdallDepartment of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-5959-8874
Tomasz HuzarskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.ORCID 0000-0003-3857-4854
Anna JakubowskaDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.ORCID 0000-0002-5650-0501
Mercedes Jimenez-LinanDepartment of Histopathology, Addenbrooke's Hospital, Cambridge, United Kingdom.ORCID 0000-0002-8164-5462
Catherine J KennedyThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-4465-5784
Byoung-Gie KimDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0002-0572-8450
Jae-Weon KimDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0003-1835-9436
Jae-Hoon KimDepartment of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.ORCID 0000-0001-6599-7065
Kayla KlettWomen's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-5155-4586
Jennifer M KoziakAlberta Health Services-Cancer Care, Calgary, Alberta, Canada.ORCID 0000-0001-5830-0397
Tiffany LaiDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.ORCID 0000-0002-3263-3895
Angela LaslavicDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-8535-6473
Jenny LesterDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.ORCID 0000-0003-4914-3275
Yee LeungDivision of Obstetrics and Gynaecology, Medical School, University of Western Australia, Crawley, Western Australia, Australia.ORCID 0000-0003-0349-8652
Na LiPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-1578-9561
Winston LiauwSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-8631-374X
Belle W X LimPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-4739-1526
Anna LinderDepartment of Obstetrics and Gynecology, Inst of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-9444-1346
Jan LubińskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.ORCID 0000-0003-2931-3003
Sakshi MahalePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-9868-0715
Constantina MateoiuDepartment of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0003-2554-949X
Simone McInernyPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-5048-1549
Janusz MenkiszakDepartment of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.ORCID 0000-0001-8279-7196
Parham MinooDepartment of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.ORCID 0000-0003-1057-0042
Suzana MittelstadtDepartment of Women's Health, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0002-0833-0544
David MorrisSt George and Sutherland Clinical School, University of New South Wales Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-9377-8521
Sandra OrsulicDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.ORCID 0000-0001-5119-8721
Sang-Yoon ParkCenter for Gynecologic Cancer, National Cancer Center Institute for Cancer Control, Goyang, Republic of Korea.ORCID 0000-0001-8325-6009
Celeste Leigh PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.ORCID 0000-0002-8023-7846
John V PearsonQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.ORCID 0000-0003-0904-4598
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0003-4891-1199
Carmel M QuinnThe Health Precincts Biobank (formerly the Health Science Alliance Biobank), UNSW Biospecimen Services, Mark Wainwright Analytical Centre, University of New South Wales Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-1003-7766
Ganendra Raj MohanDepartment of Gynaecological Oncology, King Edward Memorial Hospital, Subiaco, Western Australia, Australia.ORCID 0000-0002-0634-6833
Jianyu RaoDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-8188-1780
Marjorie J RigganDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-3701-8031
Matthias RuebnerDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-2408-1138
Stuart SalfingerDepartment of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.ORCID 0000-0002-4791-8383
Clare L ScottSir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-3689-5956
Mitul ShahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-1732-598X
Helen SteedDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-0539-8906
Colin J R StewartSchool for Women's and Infants' Health, University of Western Australia, Perth, Western Australia, Australia.ORCID 0000-0002-2165-464X
Deepak SubramanianPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-0891-9324
Soseul SungDepartment of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.ORCID 0000-0002-5801-3379
Katrina TangDepartment of Anatomical Pathology, Prince of Wales Hospital, Sydney, New South Wales, Australia.ORCID 0000-0003-2033-8052
Paul TimpsonThe Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0002-5514-7080
Robyn L WardThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-6877-8906
Rebekka WiedenhoeferInstitute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0002-7081-8604
Heather ThornePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-3610-2511
kConFab Investigators
Paul A CohenDivision of Obstetrics and Gynaecology, Medical School, University of Western Australia, Crawley, Western Australia, Australia.ORCID 0000-0002-4860-9232
Philip CroweSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-0927-3721
Peter A FaschingDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0003-4885-8471
Jacek GronwaldDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.ORCID 0000-0002-3643-2871
Nicholas J HawkinsSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-2204-3189
Estrid HøgdallDepartment of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-4689-5658
David G HuntsmanDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-4934-3322
Paul A JamesPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-4361-4657
Beth Y KarlanDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.ORCID 0000-0002-9451-2933
Linda E KelemenHollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-4362-9784
Stefan KommossDepartment of Women's Health, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0003-0534-1501
Gottfried E KonecnyDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.ORCID 0000-0001-6083-657X
Francesmary ModugnoDepartment of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.ORCID 0000-0003-0637-1534
Sue K ParkCancer Research Institute, Seoul National University, Seoul, Korea.ORCID 0000-0001-5002-9707
Annette StaeblerInstitute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0003-0103-6059
Karin SundfeldtDepartment of Obstetrics and Gynecology, Inst of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-7135-3132
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0003-0546-902X
Aline TalhoukBritish Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.ORCID 0000-0001-7760-410X
Paul D P PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8494-732X
Lyndal AndersonThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-9405-8195
Anna DeFazioThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-0057-4744
Martin KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.ORCID 0000-0002-6615-2037
Michael L FriedlanderSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-3090-795X
Susan J RamusSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-0005-7798
The University of Sydney · AUPeter MacCallum Cancer Centre · AUUniversity of California, Los Angeles · USUniversity of Pittsburgh · USSt John of God Subiaco Hospital · AUUniversity of Southern California · USAlberta Health Services · CAFoothills Medical Centre · CASahlgrenska University Hospital · SESeoul National University · KRUniversity Children's Hospital Tübingen · DEUniversity of British Columbia · CABC Cancer Agency · CAComprehensive Cancer Center Erlangen · DEGarvan Institute of Medical Research · AUSamsung Medical Center · KRSutherland Hospital · AUThe Royal Melbourne Hospital · AUThe University of Melbourne · AUThe University of Western Australia · AU
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MVECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MEpidemiology of Ovarian Cancer:New HypothesesR01CA087538 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2002 to 2006
$3.5MSteroid Hormone Genes and Ovarian Cancer RiskR01CA112523 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2006 to 2010
$3.3MEpidemiologic factors and survival by molecular subtypes of ovarian cancerR01CA168758 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DOHERTY, JENNIFER A., ROSSING, MARY ANNE · 2013 to 2016
$2.6MNCATS NIH HHS UL1 TR000124NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA168758
Abstract
purposeAdvanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating primary MOC from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathologic and gene-expression data were analyzed to identify prognostic and diagnostic features. EXPERIMENTAL
designDiscovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n = 333), mucinous borderline ovarian tumors (MBOT, n = 151), and upper GI (n = 65) and lower GI tumors (n = 55).
resultsInfiltrative pattern of invasion was associated with decreased overall survival (OS) within 2 years from diagnosis, compared with expansile pattern in stage I MOC [hazard ratio (HR), 2.77; 95% confidence interval (CI), 1.04-7.41, P = 0.042]. Increased expression of THBS2 and TAGLN was associated with shorter OS in MOC patients (HR, 1.25; 95% CI, 1.04-1.51, P = 0.016) and (HR, 1.21; 95% CI, 1.01-1.45, P = 0.043), respectively. ERBB2 (HER2) amplification or high mRNA expression was evident in 64 of 243 (26%) of MOCs, but only 8 of 243 (3%) were also infiltrative (4/39, 10%) or stage III/IV (4/31, 13%).
conclusionsAn infiltrative growth pattern infers poor prognosis within 2 years from diagnosis and may help select stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confers an adverse prognosis and is upregulated in the infiltrative subtype, which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.
Indexed as
Adenocarcinoma, MucinousGastrointestinal NeoplasmsOvarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleHumansNeoplasm StagingPrognosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.